title: The impact of received dose intensity on the outcome of advanced ovarian cancer.
abstract: It has been demonstrated that the prognosis of ovarian cancer is influenced by the dose intensity of cytotoxic treatment. The impact of received dose intensity of platinum-based combination chemotherapy on disease outcome was analysed in 226 stage III-IV ovarian cancer patients entered into two prospective randomised trials. All patients received either cisplatin or carboplatin and cyclophosphamide with or without doxorubicin for six courses after primary surgery. The impact of the received dose intensity of each drug (RDI), the average received dose intensity of the treatment regimen (ARDI) and the relative total drug dose (RTD) on progression-free survival (PFS) and survival were analysed. In the 198 patients receiving the full six courses of treatment, RDI of cisplatin or carboplatin, ARDI and RTD were > 0.76 in 74.2, 61.1 and 65.1% of cases, respectively. Although the differences were not significant, pathological complete response was more frequently observed in the group of patients with ARDI < 0.75, whereas the partial response rate was higher in the ARDI > or = 0.76 group. Median survival and PFS were 19 and 13 months; 22 and 10 months; 23 and 13 months for the groups of patients receiving chemotherapy at a ARDI of < 0.75, > or = 0.76-0.99 and > 1.00, respectively (P = not significant). It appears that modest dose modifications and brief treatment delays during first-line platinum-based chemotherapy do not affect response rate, survival and PFS in advanced ovarian cancer patients.
authors.affiliation: Department of Medical Oncology, National Institute for Cancer Research, Genoa, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Repetto
authors.forename: M
authors.initials: M
authors.lastname: Pace
authors.forename: S
authors.initials: S
authors.lastname: Mammoliti
authors.forename: M
authors.initials: M
authors.lastname: Bruzzone
authors.forename: S
authors.initials: S
authors.lastname: Chiara
authors.forename: C
authors.initials: C
authors.lastname: Oliva
authors.forename: T
authors.initials: T
authors.lastname: Guido
authors.forename: P F
authors.initials: PF
authors.lastname: Conte
authors.forename: E
authors.initials: E
authors.lastname: Campora
authors.forename: A
authors.initials: A
authors.lastname: Rubagotti
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D002945:Cisplatin